CGP 39551
CGP 39551 structure
|
Common Name | CGP 39551 | ||
|---|---|---|---|---|
| CAS Number | 127910-32-1 | Molecular Weight | 237.19 | |
| Density | 1.312 g/cm3 | Boiling Point | 434.1ºC at 760 mmHg | |
| Molecular Formula | C8H16NO5P | Melting Point | 236-239ºC | |
| MSDS | USA | Flash Point | 216.3ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of CGP 39551CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity[1]. CGP 39551 shows measurable inhibitory activity at both L-[3H]-glutamate (Ki=8.4 μM)[2]. |
| Name | [(E)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid |
|---|---|
| Synonym | More Synonyms |
| Description | CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity[1]. CGP 39551 shows measurable inhibitory activity at both L-[3H]-glutamate (Ki=8.4 μM)[2]. |
|---|---|
| Related Catalog | |
| In Vitro | CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [3H]-CPP to rat brain postsynaptic densities (PSDs) with a Ki of 310 nM[2]. |
| In Vivo | CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED50 of 4 mg/kg (p.o.)[2]. Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation[3]. |
| References |
| Density | 1.312 g/cm3 |
|---|---|
| Boiling Point | 434.1ºC at 760 mmHg |
| Melting Point | 236-239ºC |
| Molecular Formula | C8H16NO5P |
| Molecular Weight | 237.19 |
| Flash Point | 216.3ºC |
| Exact Mass | 237.07700 |
| PSA | 119.66000 |
| LogP | 0.70110 |
| Vapour Pressure | 9.46E-09mmHg at 25°C |
| Index of Refraction | 1.512 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |
CAS#:127910-31-0
CAS#:115972-31-1
CAS#:2857-97-8
CAS#:122709-16-4
CAS#:122709-17-5|
Competitive NMDA receptor antagonists and agonists: effects on spontaneous alternation in mice exposed to cerebral oligemia.
Pol. J. Pharmacol. 56(1) , 59-66, (2004) The purpose of the present study was to investigate the effects of competitive NMDA receptor antagonists,D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 37849) and its ethyl ester (CGP 3955... |
|
|
NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity.
J. Neural Transm. Gen. Sect. 106(11-12) , 1189-204, (1999) Several partial agonist and full antagonists acting at the glycine site of the NMDA receptors were tested for potential antipsychotic-like properties in rats. As models, amphetamine- and phencyclidine... |
|
|
Effects of competitive NMDA receptor antagonists on excitatory amino acid-evoked currents in mouse spinal cord neurones.
Fundam. Clin. Pharmacol. 13(1) , 67-74, (1999) The effects of CGP 37849 [DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoate] and its ethylester CGP 39551 on whole-cell currents evoked by the endogenous excitatory amino acids, L-glutamate and L-aspar... |
| 2-Amino-4-methyl-5-phosphono-3 pentenoic acid carboxyethyl ester |